Myeloma statistics

Cases

New cases of myeloma, 2014-2016 average, UK

Deaths

Deaths from myeloma, 2016, UK

Survival

Survive myeloma for 10 or more years, 2010-11, England and Wales

Prevention

Myeloma cases are preventable, UK, 2015

  • There are around 5,700 new myeloma cases in the UK every year, that's 15 every day (2014-2016).
  • Myeloma is the 19th most common cancer in the UK, accounting for 2% of all new cancer cases (2016).
  • In females in the UK, myeloma is the 18th most common cancer, with around 2,400 new cases in 2016.
  • In males in the UK, myeloma is the 16th most common cancer, with around 3,200 new cases in 2016.
  • Incidence rates for myeloma in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1990s, myeloma incidence rates have increased by almost a third (30%) in the UK. Rates in females have increased by around a fifth (21%) and rates in males have increased by a third (33%).
  • Over the last decade, myeloma incidence rates have increased by around a seventh (15%) in the UK. Rates in females have increased by more than a tenth (12%), and rates in males have increased by around a seventh (15%).
  • Incidence rates for myeloma are projected to rise by 11% in the UK between 2014 and 2035, to 12 cases per 100,000 people by 2035.
  • Myeloma in England is not associated with deprivation.
  • Myeloma is more common in Black people than in White and Asian people.
  • An estimated 17,600 people who had previously been diagnosed with myeloma were alive in the UK at the end of 2010.

See more in-depth myeloma incidence statistics

  • There are around 3,000 myeloma deaths in the UK every year, that's more than 8 every day (2014-2016).
  • Myeloma is the 17th most common cause of cancer death in the UK, accounting for 2% of all cancer deaths (2016).
  • In males in the UK, myeloma is the 16th most common cause of cancer death, with around 1,700 deaths in 2016.
  • In females in the UK, myeloma is the 16th most common cause of cancer death, with around 1,400 deaths in 2016.
  • Mortality rates for myeloma in the UK are highest in people aged 85 to 89 (2014-2016).
  • Since the early 1970s, myeloma mortality rates have increased by three-fifths (60%) in the UK. Rates in males have increased by around seven-tenths (71%), and rates in females have increased by almost half (47%).
  • Over the last decade, myeloma mortality rates have remained stable in the UK. Rates in males have remained stable, and rates in females have remained stable.
  • Mortality rates for myeloma are projected to fall by 17% in the UK between 2014 and 2035, to 5 deaths per 100,000 people by 2035.
  • Myeloma in England is not associated with deprivation.

See more in-depth myeloma mortality statistics

  • A third (33%) of people diagnosed with myeloma in England and Wales survive their disease for ten years or more (2010-11).
  • Almost half (47%) of people diagnosed with myeloma in England and Wales survive their disease for five years or more (2010-11).
  • More than three-quarters (77%) of people diagnosed with myeloma in England and Wales survive their disease for one year or more (2010-11).
  • Myeloma survival is higher in men than women.
  • Around three quarters of people in England diagnosed with myeloma aged 15-49 survive their disease for five years or more, compared with a quarter of people diagnosed aged 80 and over (2009-2013).
  • Myeloma survival is improving and has quadrupled in the last 40 years in the UK.
  • In the 1970s, around 5 in 100 people diagnosed with myeloma survived their disease beyond ten years, now it's a third.

See more in-depth myeloma survival statistics

  • A person’s risk of developing cancer depends on many factors, including age, genetics, and exposure to risk factors (including some potentially avoidable lifestyle factors).
  • 1 in 83 UK males and 1 in 116 UK females will be diagnosed with myeloma in their lifetime.
  • 14% of myeloma cases in the UK are preventable.

See more in-depth myeloma risk statistics

  • 'GP referral' is the most common route to diagnosing myeloma.
  • ‘Two-week wait’ and ’31-day wait’ standards are met by all countries, and ‘62-day wait’ is not met by any country for haematological cancers.
  • Around 7 in 10 patients with myeloma are treated with chemotherapy.

See more in-depth myeloma diagnosis and treatment statistics

Want the key stats in the sections on this page as a document? or looking for a stats report of the in-depth stats? Use the print function at the bottom of any Cancer Stats page Share this page > Print or your browser options to print or save.

Citation

You are welcome to reuse this Cancer Research UK content for your own work.
Credit us as authors by referencing Cancer Research UK as the primary source. Suggested styles are:

Web content: Cancer Research UK, full URL of the page, Accessed [month] [year].
Publications: Cancer Research UK ([year of publication]), Name of publication, Cancer Research UK.
Graphics (when reused unaltered): Credit: Cancer Research UK.
Graphics (when recreated with differences): Based on a graphic created by Cancer Research UK.

When Cancer Research UK material is used for commercial reasons, we encourage a donation to our life-saving research.
Send a cheque payable to Cancer Research UK to: Cancer Research UK, Angel Building, 407 St John Street, London, EC1V 4AD or

Donate online

We’re now on twitter.

Join the conversation and follow @CRUKHCPs for news, updates and opinion.

@CRUKHCPs

Acknowledgements

We are grateful to the many organisations across the UK which collect, analyse, and share the data which we use, and to the patients and public who consent for their data to be used. Find out more about the sources which are essential for our statistics.